Email Updates

You are here

Funding opportunity: Integrated preclinical/clinical program for HIV topical microbicides and biomedical prevention (RFA-AI-14-025)

top

National Institutes of Health
Thursday, June 12, 2014

Goal: An integrated, iterative multidisciplinary application for developing a microbicide, PreExposure Prophylaxis/PrEP), or Multipurpose Prevention Technology/MPT non-vaccine biomedical prevention (nBP) product or strategy, for use in the male and/or female genital and gastrointestinal tracts to prevent HIV acquisition/transmission. Products/strategies may be delivered by various drug delivery systems, including gels, films, quick dissolving tablets, intravaginal rings, implants, oral, and/or injection.

The purpose of this Funding Opportunity Announcement is to solicit applications from single institutions and consortia of institutions to participate in the Integrated Preclinical Clinical Program for HIV Topical Microbicides and Biomedical Prevention (IPCP-MBP).  The objective of each IPCP-MBP application is to create an integrated and iterative multi-disciplinary application with the goal of developing a microbicide, PreExposure Prophylaxis (PrEP), or Multipurpose Prevention Technology (MPT) non-vaccine biomedical prevention (nBP) product or strategy, for use in the male and/or female genital and gastrointestinal (GI) tracts to prevent HIV acquisition/transmission. Products and strategies may be delivered by a variety of drug delivery systems (DDS), including gels, films, quick dissolving tablets, intravaginal rings (IVR), implants, oral, and/or injection. This FOA contains significant modifications to previous iterations of the Integrated Preclinical Clinical Program FOA. - See more at: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-025.html#sthash.6hsz7O1E.dpuf